{"entity":{"id":"nct05608876","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","aka":[],"tldr":"A phase 2 trial of Tigilanol Tiglate in head and neck squamous cell carcinoma, run by QBiotics Group Limited, active and no longer recruiting.","summary":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer is a phase 2 interventional study registered as NCT05608876 by QBiotics Group Limited, with 15 participants enrolled, started 2022-11-03 and due to reach its primary completion in 2025-07-31. Interventions recorded: Tigilanol Tiglate.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05608876","url":"https://clinicaltrials.gov/study/NCT05608876"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["qbiotics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05608876","phase":"2","setting":"A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies","sponsor":"QBiotics Group Limited","enrolled":15,"outcomes":[]},"route":"/trials/nct05608876/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/"}]}}